Introduction
Cancer invasion and metastasis is influenced by small bioactive peptides such as endothelin-1 (ET-1) which can exert an autocrine (epithelial) or paracrine (stromal) influence on growth. ET-1 is generated from its inactive precursor big-ET-1, by endothelin-converting enzyme (ECE-1). There are 4 distinct isoforms, ECE-1a, ECE-1b, ECE-1c and ECE-1d, which differ only in their N-terminal regions. All isoforms are derived from a single gene through the use of alternative promoters but each isoform has a different cellular localisation pattern. This study investigated the expression and localization of the ECE-1 isoforms in prostate cancer stromal-epithelial components and examined their interaction using Matrigel invasion chambers.
Materials and Methods
The epithelial cell lines utilised here were androgen-sensitive LNCaP, androgen-independent PC-3, Du145 and nonmalignant, transformed, PNT1-a, PNT2-C2 and P4E6 prostate cells. Cells derived from malignant and benign tissue from radical prostatectomy have also been exploited.
Results
Previously we have reported that specific inhibition of endogenous ECE-1 activity in stromal cells significantly reduced PC-3 and Du145 invasion. Supplementation of defined media with bradykinin and ET-1 significantly increased PC-3 and Du145 invasion. Our present data show siRNA duplexes targeted to ECE-1 reduced protein expression by 70% in stromal cells. Subsequent Matrigel invasion assays using these ECE-1 knocked down stromal cells resulted in a 70% reduction in PC-3 invasive capacity. No significant effect was observed using a "nonsense" siRNA control duplex. Data showed that all four ECE-1 isoforms were present at the mRNA level in all epithelial cell lines tested. However, all cell lines lacked both ECE-1a and ECE-1b protein expression. ECE-1c protein is expressed in PC-3, Du145, PNT2-C2 and PNT1-a while LNCaP and P4E6 lack ECE-1c expression. We further examined effects of specific isoforms and found that overexpression of ECE-1c by transient transfection increased PC-3 invasion by 20%, whereas, ECE-1a and ECE-1b decreased PC-3 cell invasion by ~50%. Transient expression of ECE-1c in PNT1-a cells, a low invasive cell line which lacks ECE-1, increased invasion of these cells 150%, whilst, cotransfection with ECE-1a and ECE-1b increased invasion by ~20% and 40% respectively. Co-transfection of either ECE-1a or ECE-1b with ECE-1c completely suppressed ECE-1c influence on invasion in PNT1-a cells.
Conclusion
These results suggest that ECE-1c activity can be suppressed in the presence of either ECE-1a or ECE-1b. The suppressive ability of particular ECE-1 isoforms in PC invasion is a novel observation and is currently being investigated further.
Introduction
The rectum is a principal dose limiting organ for prostate radiotherapy. Toxicity is related to both the dose and volume of rectum irradiated. There is an association between the degree of rectal distension and A-P prostate movement. This study quantifies prostate motion and assesses whether both the anterior and posterior margins of the radiotherapy field can be individually adapted according to the degree of rectal distension.
Materials and Methods
Prostate motion was determined in 25 patients undergoing radical radiotherapy for prostate cancer. This was assessed by the co-registration and fusion of 2 localisation CT scans over a 35 minute interval. Rectal distension was determined using a subjective assessment score into large, moderate or small, based on the initial CT scan. The proportion of patients who had adequate coverage of the prostate after taking movement in the A-P direction was then calculated using a variety of anterior and posterior margins for each of the rectal groups.
Results
The median values (inter-quartile range) for prostate motion in the A-P, S-I and L-R directions were 1.2mm (0.6-3.1mm), 1.2mm (0.5-2mm), and 0.6mm (0.4-1.2mm) respectively. Overall a 3mm margin would account for lateral movement, and 6mm margins in both S-I and A-P dimensions. For those with large rectal distensions, a 6mm posterior and 2mm anterior margin could account adequately for prostate movement, whilst for those with small rectal distensions, a 4mm posterior and 3mm anterior margin were required. Those with moderate rectal distension required a larger anterior margin of 6mm with a smaller posterior margin of 1mm in order to achieve full coverage of the prostate. Conclusion Adapting the A-P margin according to the degree of rectal distension provides a feasible approach to dealing with A-P prostate motion avoiding the need for increasing the radiotherapy treatment volume.
Trafficking of androgen receptor coregulatory molecules in stable transfectants of prostate epithelial cells
Richard Birnie and Norman J. Maitland YCR Cancer Research Unit, Dept. of Biology (Area 13), University of York, Heslington, York. YO10 5DD.
Introduction:
Discrete localisation to distinct subcellular compartments is a common regulatory mechanism in many signalling pathways, including the androgen receptor axis. Androgen receptor is a ligand activated transcription factor localised to the cytoplasm in the absence of ligand that translocates to the nucleus upon stimulation with dihydrotestosterone (DHT). It has long been known that AR exists in the cytoplasm as a monomer in complex with heat shock proteins, in particular hsp90.
Previously, hsp90 has been viewed purely as a chaperone responsible for regulating protein folding and stabilising AR in the absence of ligand. More recently, the role of hsp90 as an active coregulator of androgen receptor and a potential therapeutic target in prostate cancer is beginning to be elucidated. Here we describe the translocation of hsp90 to the nucleus in two non-malignant prostate epithelial cell lines carrying a stable transfection with wild type human androgen receptor.
Materials and Methods:
The time course of translocation for AR and Hsp90 was determined by immunocytochemistry using specific monoclonal antibodies, anti-AR clone F39.4.1 (Biogennex) and anti-hsp90 clone 68 (BDbiosciences) respectively). Nuclear and cytoplasmic protein fractions were generated based on differential detergent solubility and analysed by western blotting for the presence of AR or hsp90.
Results:
The cell lines ARWT115 and ARWT124 were developed previously in our laboratory. Both lines a stably express wild type human androgen receptor cDNA which is located on an extra chromosomal episome. The androgen receptor pancellularly distributed in ARWT cells in the absence of ligand. Nuclear translocation is detectable within 30 min in response to 10nM DHT or 100nM bicalutamide. In DHT-treated cells 100% nuclear localisation is achieved within 4h, cytoplasmic AR is still detectable up to 8h after treatment with bicalutamide. Nuclear translocation of Hsp90 was observed 24h after plating in both ARWT cell lines but not in LNCaP cells or parental androgen receptor negative PNT1A cells. This was confirmed by western blotting of cytoplasmic and nuclear fractions derived from all 4 cell types. ARWT115 showed approximately 40% of total hsp90 to be nuclear in comparison to ~20% in ARWT124 cells irrespective of hormone treatment. Less than 15% of Hsp90 was nuclear in PNT1A cells and it was undetectable in LNCaP cells a common model of AR function in prostate.
Conclusions:
We have shown that AR translocates rapidly and completely to the nucleus in response to 10nM DHT within 4h, whereas only partial translocation is seen in response to 100nM bicalutamide up to 8h. Hsp90 was found to translocate to the nucleus more slowly than androgen receptor in non-malignant PNT1A cells but not LNCaP prostate cancer cells. In addition, hsp90 translocation was dependent on androgen receptor expression but independent of ligand. The dependence of the hsp90 phenotype on AR expression is likely to be indirect since hsp90 translocation occurs more slowly than AR translocation. These data suggest that alterations in the interaction between AR and hsp90 may be a potentially significant difference between malignant and non-malignant prostate cells.
Introduction:
Prostate cancer is the second leading cause of male cancer death. The human androgen receptor (hAR) is a nuclear transcription factor that plays a pivotal role in prostate cancer progression and its development to hormone-refractory disease. The unliganded hAR is cytoplasmic and becomes activated by binding its cognate ligand, 5α-dihydrotestosterone, when it then translocates into the nucleus and exerts its effects by binding to androgen response elements of target genes, thereby regulating their expression. The importins are nuclear import proteins which can recognise and bind to specific amino acid motifs of cargo proteins and drive them through the nuclear pores. No direct protein binding has been reported for the importins with the hAR or other steroid receptors, although a functional role has been recently reported for the glucocorticoid receptor (Freedman ND et al, Mol Biol Cell. 2004; 15(5):2276-86) . The determination of the key proteins involved in the nuclear import pathway of the hAR will provide valuable preliminary knowledge for new therapeutic intervention strategies.
Materials and Methods:
We have investigated the binding between bacterially expressed C-terminal His and GST fusion proteins for importin α and the hAR respectively. The cell lysates for the Importin α and hAR were mixed and in vitro binding assays performed using the appropriate affinity resins (nickel or glutathione sepharose) to pull-down protein complexes. The results were analysed using SDS-PAGE and Coomassie stain. Using a secondary structural approach, truncation mutagenesis was performed to engineer a series of GST-hAR constructs to determine the minimal domain required for interaction.
Results:
We have established that a region of the hAR, encompassing its DNA binding domain, hinge region and ligand binding domain binds directly to importin α, a nuclear import receptor. This finding was reproducible using either affinity resin. We have extended this novel finding by carrying out truncation mutagenesis of the hAR and established a minimal region of interaction (less than 70 amino acids) within its DNA binding and hinge domains. This demonstrates that the hAR hinge and DNA binding domains contain a key region for its direct interaction with importin α.
Conclusion:
We have established that the hAR binds directly to the nuclear import protein, importin α, and determined a minimal sequence sufficient for this binding. These findings extend previous work reporting a nuclear localisation signal (NLS) motif within this region and propose a mechanism for nuclear import. Such preliminary knowledge provides valuable insight to prostate
Introduction:
In the absence of a long-term effective treatment for advanced stage prostate cancer, there is emphasis on development of new rational strategies to eradicate primary tumours and metastases. Gene therapy remains an attractive option given the range of specific gene products expressed in the prostate. Available vectors for gene delivery include viruses and non-viral systems. However, serious safety issues surround some of these viral vectors, whereas non-viral systems are generally less efficient. Here, we describe an exciting new viral vector with significantly enhanced safety over other viruses. An insect virus, the baculovirus, is non-replicative in mammals and is unable to express any of its viral genes, as shown by RT-PCR.
Materials and Methods and Results:
We have produced a series of recombinant baculoviruses, encoding a CMV-EGFP reporter gene cassette, which can efficiently transduce, and express EGFP in human prostate cell lines in vitro, human prostate tissue ex vivo, and orthotopic prostate tumours in mice in vivo. To target transduction to the prostate, the major virus envelope protein, gp64, was genetically modified to encode peptide insertions that facilitate virus attachment either through direct ligand:receptor interactions or via antibodies raised against cell surface proteins overexpressed in prostate cancer. Binding specificity of these modified viruses and soluble gp64 proteins are currently being evaluated. Preliminary results suggest that a peptide targeted virus has a transduction advantage over the wild-type envelope virus. Double targeting to ensure specific expression of therapeutic or marker genes in prostate cells will be achieved by controlling expression of the therapeutic gene with a 'prostate-specific' promoter. Specific mutations were introduced into a 4.5kb fragment of the promoter from human prostate specific transglutaminase (hTGp) gene to delete retinoic acid response elements that may play a significant role in the tight regulation of this promoter. This gene exhibits the most prostate-specific expression pattern from those we have surveyed. The effects of these mutations on promoter strength and specificity are being investigated, with the future aim of developing a strong but highly prostate specific promoter.
Conclusion:
There is great potential to produce highly efficient, doubletargeted and thus highly specific gene therapy vectors, based on the baculovirus, providing improvement on current technology in terms of efficiency and safety.
Salvage radiotherapy for biochemical failure following radical prostatectomy: a case series *Shah Z., *Fahmy A., Vakkalanka B.K., *Desai K., *Blacklock A.R.E., Stockdale A.D. Coventry Radiotherapy and Oncology Centre and *Department Of Urology, University Hospitals of Coventry and Warwickshire, Coventry, U.K.
Introduction:
A retrospective analysis of the outcome of radical prostatectomy for prostate cancer in a single centre and assessment of the role of salvage radiotherapy for patients with biochemical relapse. Patients and Methods: 137 patients underwent radical prostatectomy (RP) for adenocarcinoma of the prostate in our centre between December 1994 and June 2003. 54 of these patients developed a biochemical relapse (PSA ≥0.2) and 1 had a clinical and biopsy proven recurrence. 27 patients including 5 from elsewhere received salvage radiotherapy (RT). 24 of these had positive margins at resection and 3 had involvement of seminal vesicles. 7 had Gleason score 8≥ (26%). Median PSA before RT was 0.6ng/ml (range 0.2-5.0). Median age at surgery was 63.5 years (range 52-71). Median age at radiotherapy was 65 years (range 53-73). Median time to biochemical relapse was 10.5 months (range 0-35) and median interval from surgery to RT was 22.5 months (range 3-71). 5 patients received neo adjuvant hormones. 22 patients received 64 Gray in 32 fractions, 3 patients 55Gray in 20 fractions and 2 patients 50 Gray in 20 fractions. Comparison is made with 32 patients managed by observation or hormone therapy. Results: 24 patients (89%) achieved complete biochemical remission following RT. 15 (56%) of these remain in complete remission with a median follow up 17 months (range 10-46).
Conclusions:
Salvage radiotherapy is an effective treatment for achieving biochemical remission in selected patients who relapse following radical prostatectomy. 
Introduction:
Prostate cancer cells express a broad complement of nuclear receptors including not only the androgen receptor but others such as the peroxisome proliferator activated receptors (PPAR). PPARs are attractive therapeutic targets and form the rational for examining novel ways to target these receptors. The antitumour effects of nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently thought to be mediated via cycloooxygenase inhibition. However our recent x-ray crystallography studies have demonstrated NSAIDs (indomethacin and flufenemic acid) bound to AKR1C3, an aldo-ketoreductase enzyme, suggesting that AKR1C3 inhibition may be central to the actions of these drugs. Previously in myeloid leukemia cells, which do not have functional androgen responses, we established a novel mechanism by which AKR1C3 negatively regulates ligand availability for PPARγ, thereby limiting receptor actions and attenuating cell differentiation. Both NSAIDs drugs, such as indomethacin, and medroxyprogesterone acetate share in common not only the capacity to inhibit AKR1C3, but have potential therapeutic benefit against prostate cancer. The current translational study unites diverse expertise and a unique range of tools to establish the significance of these mechanisms in prostate biology.
Materials and Methods:
In silico and in vitro protocols measured PPARs and AKR1C3 levels, for example quantitative reverse transcription real time PCR (Q-RT-PCR) to measure PPARs and AKR1C3 mRNA levels in a panel of non malignant (PNT2, RWPE-1) and malignant (P4-E6, LNCaP, PC-3 and DU-145) cell lines. Parallel mRNA from a panel of primary normal and tumour cultures complimented these studies. Antiproliferation studies were undertaken in cell line models with a range of small molecular weight inhibitors towards AKR1C3 (MPA and indomethacin) alone and in combination with ligands for PPARs.
Results:
We found in silico that prostate cancer cells express increased AKR1C3 levels compared to normal counterparts. In the panel of primary material AKR1C3 levels were clearly detected in primary tumours. Where these levels were elevated, reflecting the in silico data, there tended to be a reciprocal downregulation of PPAR and γ levels suggesting a combined ablation of PPAR-mediated signaling. These expression patterns are being explored and confirmed in the cell line panel. Our initial studies on the antiproliferative action of AKR1C3 inhibitors in the cell line panel demonstrated that the NSAIDs and MPA demonstrated a range of antiproliferative effects, irrespective of AR background. Combination studies with the clinically acceptable PPARα ligand bezafibrate resulted in a range of co-operative behaviors, the extent of which was determined by cell background. Thus in non-malignant RWPE-1 cells the AKR1C3 inhibitors plus bezafibrate displayed additive interactions. By contrast these interactions were squelched in PC-3 and DU-145 cell backgrounds.
Conclusions:
These data demonstrate that AKR1C3 is expressed in prostate cancer cells and may form a target for a combined strategy to target PPAR receptors, with clinically acceptable and safe drugs, as part of a novel chemotherapy.
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Introduction:
In order to develop improved treatment strategies for patients with progressive prostate cancer, it is important to understand the molecular mechanisms by which this common malignancy becomes increasingly aggressive. Gene expression profiling has implicated the Polycomb Group (PcG) protein EZH2 in the progression of prostate cancer. PcG proteins have been characterised in developmental organisms and are known to play a highly conserved role in transcriptional silencing of genes during embryonic development. More recently, the PcG protein EZH2 has been implicated in the control of cell proliferation in a variety of cell types. Here we show that EZH2 promotes prostate cancer cell proliferation and invasion in vitro.
Materials and methods:
Briefly, human prostate cancer cell lines were transiently transfected with small inhibitory RNA (siRNA) molecules specific for EZH2 mRNA, in order to attenuate expression of EZH2. Efficient knockdown of EZH2 mRNA was shown by semi-quantitative RT-PCR and EZH2 protein by western blot. The proliferation phenotype of siRNA transfected cells was investigated using a cell proliferation assay employing conversion of MTT substrate, whilst cellular invasion was assayed using quantification of Matrigel invasion.
Results:
siRNA-mediated knockdown of EZH2 causes markedly reduced cell proliferation in a normally rapidly proliferating prostate cancer cell line. Furthermore, EZH2 knockdown also reduces the ability of this prostate cancer cell line to invade in vitro.
Conclusion:
These Here we test the functional significance of these modifications in the development of hormone refractory prostate cancer.
Materials and methods:
Protein expression of AR phosphorylated at the Akt consensus site Serine 210 (phospho AR)(Immgenex) and phosphorylated Akt at Serine 473 (Cell signalling) was determined by immunohistochemistry in a cohort of matched tumour pairs (one taken before and one after hormone relapse) from 53 prostate cancer patients. Detection and visualisation was achieved using the LSAB + kit (DAKO Cytomation) for phospho AR) or EnVision (DAKO Cytomation) (phospho Akt) and DAB kit (Vector Laboratories). Two independent observers using a weighted histoscore method scored each section.
Results:
Phospho AR expression was significantly higher in hormone resistant tumours compared to matched hormone sensitive tumours (107.5(57.5-175.5) vs 50(0-92) p=0.0005). Further, patients with phospho AR expression above the median value in hormone refractory tumours had significantly shorter survival from time of biochemical relapse than patients with low (below the median) phospho AR expression (p=0.0076), this was also observed for shorter overall survival (p=0.034). Almost half the patients in this study showed a marked increase in phospho AR expression with the development of hormone refractory disease (47%, 25/53). In these patients a significant reduction in time to death from biochemical relapse (p=0.0004) and overall survival (p=0.023) was observed relative to patients who had a decrease in phospho AR expression (8%, 4/53) 
Introduction
Prostate cancer is the second leading cause of male cancer death in the UK. Whilst the disease remains localised and treatable in the majority of patients, metastatic disease affects significant numbers and there is a major research effort to understand the molecular basis for this. An emerging theme is the subversion of normal androgen-mediated signaling through changes in the expression of coactivators and corepressors and cross-talk from growth factor and cytokine signaling pathways.
In the last few years evidence has emerged that many components of these growth factor signaling pathways, including the receptors themselves and adaptor proteins required for their internalization from the cell surface may also be trafficked into and out of the nucleus. If true this brings into question the idea of a spatial separation between activated, nuclear androgen receptor (AR) and such components of these other signaling pathways. Our preliminary work has focused on one example of a membrane trafficking adaptor, Huntingtin Interacting Protein (HIP1), which has previously been found to be overexpressed in prostate cancer.
Materials and Methods
We have investigated the subcellular localization of HIP1 in transfected COS7 cells and in the LNCaP cell lines using confocal microscopy and by fractionating and blotting nuclear and cytosolic fractions from these cell-lines. We have gone on to use luciferase reporter assays with a Prostate Specific Antigen (PSA) promoter driven construct to examine the effects of changing expression levels of HIP1 (transfection and siRNA) on AR-mediated transcription.
Finally, chromatin immunoprecipitation has been used to test whether HIP1 is recruited to proximal and distal response elements in the PSA promoter.
Results
We have established that a fraction of HIP1 is nuclear and has a co-regulatory effect on AR-mediated transcription. Reducing the expression level of HIP1 both decreases PSA expression in LNCaP cells and also lowers the steady-state protein level of AR. Conclusions Whilst proteins such as HIP1 have in the past been regarded as modulators of growth factor receptor signaling because of their functional role in the internalization and trafficking of activated cell surface receptors, our data reveal a second effect on the transcriptional activity of the AR. Whether this is directly due to the nuclear trafficking of HIP1 remains to be demonstrated but the existing study constitutes the first evidence of the effects of such of protein on a defined transcription factor, raising the possibility of physical as well as enzymic cross-talk effects between growth factor and AR signaling pathways. 
Introduction:
Prostate cancer is increasingly prevalent in our ageing Western Society. Despite recent advances in the detection of early prostate cancer there remains little effective therapy for patients with locally advanced and/or metastatic disease. The goal of existing therapies for prostate cancer has been to eradicate the bulk of cells within a tumour. However, most patients go on to develop androgen-independent disease that remains incurable by current treatment strategies. The major unanswered question remains as to the origin of this resistance: is it the acquisition of drug resistance by the cancer cells as they evolve or is it that existing therapies fail to kill cancer stem cells effectively? Here, we show that we can distinguish the tumour-initiating from the non-tumour-initiating cells based on cell surface marker expression.
Materials and Methods:
Putative tumour stem cells were isolated using rapid adhesion to type I collagen and magnetic cell sorting. 
Introduction:
The androgen receptor (AR) is a member of the nuclear receptor family of transcription factors and plays a critical role in regulating expression of genes involved in prostate growth, homeostasis and androgen-dependent and -independent tumour formation. A likely requisite for AR activity is the binding of histone acetyltransferase (HAT)-containing co-activator proteins that, by directly acetylating both histones within androgen-responsive genes and the receptor itself, facilitate androgen-dependent gene expression. In contrast, AR-mediated transcription is abrogated by the deacetylase activity of histone deacetylase 1 (HDAC1) suggesting that changes to the acetylation status of the receptor provides an important facet of AR regulation. We have recently shown that the E3 ubiquitin ligase Mdm2 associates directly with active AR-responsive genes and catalyses the ubiquitylation and destruction of components of the AR transcriptosome, including both AR and HDAC1, indicating an additional mechanism for controlling the androgenic response. That HDAC1 is a substrate for Mdm2-mediated ubiquitylation prompted a search for additional E3 ligases that could target the deacetylase for modification and thus provide evidence of distinct modes of HDAC1 regulation.
Materials and Methods.
Standard techniques using the LNCaP prostate cancer cell line included immunoprecipitation, siRNA knockdown and both chromatin immunoprecipitation (ChIP) and re-ChIP analysis, an extrapolation of ChIP allowing protein-protein interactions to be detected at active genes Results.
Here we show that the ubiquitylase hPirh2 interacts directly with HDAC1 catalysing ubiquitylation and destabilisation of HDAC1 in vivo. Furthermore, siRNA knockdown of hPirh2 increases HDAC1 protein levels that subsequently decreases transcriptional activity of the AR. Our ChIP data provides evidence that HDAC1 and hPirh2 are not only recruited, but co-associate upon the active androgen-responsive PSA gene suggesting that HDAC1 ubiquitylation likely occurs at the promoter level.
Conclusion.
In all, our data provides a novel insight into the regulation of HDAC1 that is pertinent in the AR signalling cascade and may provide future therapeutic targets for prostate cancer treatment.
Human bone marrow stromal cell derived IGFs enhance cell population growth and androgen regulated gene expression in human prostate cancer cells. Eaton C.L., Papageorgiou M., Lippitt J., Nyambo R., Cross N., Hamdy F.C. Academic Urology Unit, University of Sheffield, UK
Introduction:
More than 50% of patients with metastatic prostate cancer have skeletal involvement in their disease. The colonization of bone by prostate cancer cells suggests that there are survival advantages for these tumour cells associated with growth in this site. Bone derived influences on prostate cancer cell survival are beginning to be identified and we have recently shown (1) that osteoprotegerin, a protein produced by human bone marrow stromal cells (hBMSCs), can suppress the effects of TRAIL (TNF-related apoptosis inducing ligand), a proapoptotic cytokine that specifically targets tumour cells. In the present study we have further evaluated hBMSC for the production of other factors that could potentially influence the survival/activities of prostate cancer cells.
Materials and methods:
hBMSC have been previously isolated from bone biopsies and grown/characterised in our laboratories (1). Medium was conditioned over confluent cultures of these cells for use in subsequent experiments. The human androgen sensitive prostate cancer cell line LNCaP and the androgen independent prostate cancer cell line PC3 were challenged with doses of up to 50% hBMSC conditioned medium (CM) over time courses and effects on cell population growth evaluated. In experiments with LNCaP cells, steroid free CM was used and the effects of this medium on PSA (prostate specific antigen) secretion evaluated by ELISA. PSA gene expression in these cultures was assessed by quantitative (Q)RT-PCR. The effects of conditioned medium on LNCaP were compared with the effects of dihydrotestosterone (DHT, 1nM). In later experiments, factors with putative effects on tumour responses were specifically removed from CM by immunoprecipitation and medium re-evaluated for previously observed activity.
Results:
Expression of TENB2 (TMEFF2) 
Introduction:
The development of anti-androgen resistant prostate cancer represents a major problem in the urology clinic and the search for new therapy targets associated with this condition is the focus of much research. Using a prostate cancer model TEN12 and its subline TEN12F, a gene TENB2, (TMEFF2) was found to be differentially expressed in the androgen independent subline and was also present in prostate cancer specimens (Glynne-Jones et al. Int J Cancer 2001; 94:178-84) . The predicted protein was a single pass membrane protein with an EGF and two follistatin domains. In the present study the expression of TENB2 in prostate cancer and BPH specimens has been assessed in relation to disease progression and survival.
Methods:
Formal saline or Bouins fixed archival specimens of prostate cancer and BPH together with formal saline fixed xenografts were assessed by immunocytochemical (ICC) techniques, using a specific monoclonal to TENB2 (Berlex Biosciences). The antibody specificity was evaluated by Western blotting and ICC analysis of recombinant protein in transfected cell lines and on sections of xenografts of TEN12 and its sublines. Serial sections of the prostate tumours were also analysed for proliferation by ICC of MIB-1.
Results:
In the model system the androgen dependent TEN12 line exhibited low cytoplasmic staining pattern with the antibody whilst the androgen independent lines TEN12F, TEN12FM and TEN12C gave strong cytoplasmic and membranous staining. On Western blotting of the recombination TENB2 protein one band of 56kD was detected with the antibody. The pattern of TENB2 expression in the prostatic cancer samples varied some tumours exhibiting diffuse or granular cytoplasmic staining but in others strong membrane staining was also evident. A significant increase in TENB2 expression was observed in primary prostate cancers (n=104) compared to BPH samples (n=32). The highest expression of the protein was associated with the poor histological grades (p<001). No relationship was however found with metastatic status or with proliferation (MIB-1 scores). Analysis of a few pre-and post-treatment samples (n=11) gave no consistent change in expression of this protein. In a small group of patients (n=41), in which survival data was available and whose tumours had been fixed in Bouins fluid, the TENB2 expression appeared to be unrelated to survival. In a further set of formal saline fixed carcinomas Medium conditioned by hBMSCs significantly increased LNCaP and PC3 cell numbers over 10 days in cell culture (ttest p<0.001). In LNCaP, this effect was as potent as challenge of cells with DHT over the same time frame and in both cell lines the effects of CM could be significantly reversed by immunoprecipitation of insulin-like growth factors (IGFs) I and II from CM (p<0.01). PSA secretion and expression by LNCaP was significantly induced by either challenge with CM or with DHT(p<0.001).The effects of CM on PSA secretion/expression could be significantly reversed by removal of IGFs (p<0.001). Co-challenge of LNCaP cells with DHT and CM resulted in increased PSA expression and a 5 fold induction of PSA secretion compared to either DHT or CM treatment alone (p<0.001). This effect was partially reversed by removal of IGFs from CM.
Conclusions:
This study suggests that hBMSC derived IGFs are potential growth/survival enhancers of both androgen sensitive and independent prostatic cancer cells. The ability of these factors to enhance and in some cases replace the effects of DHT in the androgen sensitive LNCaP may suggest a role for these factors in loss of hormone sensitivity in prostate cancer.
(n=90) no significant difference was found whether the survival data was analysed either as one group or when the patients were stratified according to metastatic status (M0=59, M1=30).
Conclusion:
In prostate cancer specimens TENB2 expression was significantly increased over that seen in the BPH and was also associated with the higher histological grades. The preliminary data on survival however do not support its' candidature as a prognostic marker. The association of membrane expression with androgen independence in the TEN12 prostate cancer xenografts models requires clarification in the clinical samples of this malignancy.
Flow Cytometry as a Tool for Studying Prostasomes
George Delves, Anuj Goyal, Alistair Stewart, Alan Cooper Portsmouth University and the Solent Department of Urology Introduction Prostasomes are exosomes liberated from prostate epithelial cells, eventually appearing at high density in seminal plama. Analogous bodies are also secreted by prostate cancer cells at primary and metastatic sites as well as in vitro by cell lines. They are small particles varying in both size 50-400nm diameter and density as seen by transmission electron microscopy. Preparation of purified prostasomes requires time and a relatively large starting volumes of (pooled) semen. This study describes their identification by analytical flow cytometry, opening up the possibility of studying individual semen specimens and assessing changes in composition with disease or fertility status.
Materials & Methods
Purified prostasomes, prepared by ultracentrifugation and gel filtration and cellular exosomes retrieved from PC3 cell culture supernatants were labelled with a fluorescent aliphatic, lipidlike membrane marker (PKH26), to distinguish them from the particulates that are normally classed as "debris" in cell FITC and with lycopene, which parallel HPLC studies show to incorporate into prostasomes.
The (relatively weak) fluorescence characteristics of lycopene were validated by visualising droplets microscopically. Data was acquired on a FACSCalibur cytometer with the forward scatter set to E-0 and both physical parameters on log scale.
Results
The purified prostasome preparations formed a discrete region in dot-plot displays, identified and distinguished from other particulates not only by fluorescence, but by their physical characteristics. The same populations (with or without PKH labelling) bound Annexin-V and incorporated lycopene during short pre-incubations. There was, however, no evidence for the dual morphologies seen on electron microscopy. PC3 exosomes also localised well on the acquisition graphics but were between five and ten-fold smaller as assessed by forward scatter. Conclusions Flow cytometry can be applied to the study of prostasomes and cellular exosomes. Their composition can be studied within the boundaries set by the equipment available and the ability to label moieties of interest. Options for rapidly investigating samples from individual samples are expanded.
One apparent by electron microscopy. 
Introduction
The plasma membrane represents the constantly changing interface between the cell and its environment. The proteins expressed at the cell surface have wide ranging effects on cellcell contacts, cell migration, signaling and signal transduction. These exposed proteins are readily accessible and have the potential to provide new therapeutic targets or markers for the detection and treatment of prostate cancer. For this study we have used the androgen responsive LNCaP cell line as the basis for profiling proteins at the cell surface, in particular those which are androgen regulated.
Materials and methods
LNCaP cells, no later than passage 15, were grown in RPMI supplemented with 10% fetal bovine serum (FBS) until 60% confluent. Cells were washed in PBS and grown for a further 24 hours in phenol red free RPMI supplemented with charcoal stripped FBS before being treated with either 10nM R1881, 1µM
unable to pass through the membrane. Biotinylated proteins were purified using a monomeric avidin column and detergent was removed using dialysis. Membrane proteins were concentrated using TCA precipitation and the resulting samples resuspended in 9M urea buffer for analysis using SDS-PAGE and two-dimensional gel electrophoresis (2-DE).
Results
Using this method we can demonstrate efficient and reproducible isolation of LNCaP membrane proteins. Control experiments indicate that we have effective membrane protein isolation free of contamination from high abundance cytosolic proteins such as actin. We have successfully identified a number of well known plasma membrane proteins at th e surface of LNCaP cells. Using 2-DE we have noted that th remains unchanged in response to androgens. Of the proteins that do alter in response to androgens one example is the well known prostate cancer progression marker E-cadherin. Ecadherin expression at the cell surface alters in response to androgens and antiandrogens independently of expression levels seen in whole cell lysates.
Conclusion
Our results indicate that we can successfully isolate, purify and identify prostate cell membrane proteins. Work is ongoing to confirm the cell surface expression of specific proteins in a number of different prostate cell lines, primary prostate cells and patient samples with a view to developing new prostate cancer progression markers or therapeutic targets. 
Aim
Radiotherapy has an important role in early and locally advanced prostate cancer. Tumour hypoxia, reflected by high vascular endothelial growth factor (VEGF) expression, is associated with a poor response to radiotherapy. In this pilot study we investigated the relationship between VEGF expression and outcome following radiotherapy in men with localised prostate cancer.
Method
Prostate biopsies were obtained from 44 men with T3 prostate adenocarcinomas treated with radiotherapy. These were stained for VEGF expression using immunohistochemistry, staining was assessed only in malignant cells and scored by two independent observers. Overall survival was compared using Kaplan-Myer curves and log rank analysis. Results 21 men were categorised as high VEGF expression and 23 with low expression. The group with high VEGF expression had a significantly poorer overall survival compared to the low VEGF expression group (P=0.038). There was no significant difference in other recognised prognostic markers (Gleason score, PSA) between groups. Conclusion This pilot study is the first to show that tumour hypoxia (high VEGF expression) could be used to identify men with prostate cancer destined to show a poor response to radiotherapy.
Prediction of biochemical failure in patients with positive margins post radical retro-pubic prostatectomy and lymph node dissection. Anna O'Riordan, Anand Patel, Phil Keegan, Sri Nagarajan, David Chadwick. James Cook University Hospital, Middlesbrough.TS4 3BW.
Introduction:
The aim is to determine factors that predict biochemical failure in patients with positive margins post radical retro-pubic prostatectomy (RRP) and lymph node dissection. Materials and Methods: 290 patients who underwent RRP, by a single surgeon, between 1996 and 2002 were evaluated. Biochemical recurrence was classified as a PSA >0.2µg/l. The incidence, location, number of positive margins, Gleason grade, pathological stage, as well as the time to recurrence was determined.
Results:
Surgical margins were positive in 83 men (28.6%). Of these 7 were excluded: follow-up was unavailable for one patient, and the other 6 had lymph node micrometastases and received immediate hormone treatment. Of the remaining 76 men, 32 relapsed (42.1%). Uni-variate analysis (Cox regression) revealed that PSA, Gleason grade, number positive margins and stage all significantly predicted a reduced time to biochemical recurrence. Also, patients who presented with symptoms had a better outcome. In multivariate analysis, PSA (p=0.014) and stage of the disease (T2 vs T3) (p=0.003) had prognostic value, independent of the other factors tested, for predicting time to relapse.
Conclusion:
In patients with positive margins post RRP, pathological stage (T2 vs T3) and PSA (continuous) are the most important factors in predicting a poor outcome. show that the patients undergoing TRUSP has a statistical significant greater level of anxiety before the procedure. This appears not to be the case with male patients attending urodynamics. The result can be explained by the fact that TRUSP involves the possibility of prostate malignancy. With the increased incidence of TRUSP procedures, a greater appreciation of the effect of such a procedure on the patient is required.
Conclusion
There is a greater level of anxiety in male patients undergoing TRUSP than urodynamics. This may reflect the possibility of a diagnosis of malignancy.
The prevalence of reported erectile dysfunction in male patients referred for urodynamics Belal M, Al-Hayek S, Sivalingam S, Professor Abrams P. Bristol Urological Institute, Southmead Hospital, Westbury-onTrym, Bristol, UK.
Introduction
Recent studies, based on postal questionnaires, have suggested a strong association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). The aim of this study is to examine a relationship exists in male patients referred for urodynamics, with and without bladder outlet obstruction (BOO) with erectile dysfunction (ED).
Materials and methods
From 1994 to 2004 male patients who attended our urodynamic unit for filling cystometry and pressure flow studies were identified. The presence of erectile dysfunction (ED) was ascertained by direct questioning by the physician prior to the urodynamic investigation. The diagnosis of bladder outlet obstruction was based on bladder outlet obstruction index as defined by the ICS standardisation committee. 
Results

Discussion
There is a significant proportion of patients referred for urodynamics reporting erectile dysfunction. Reporting levels do not significantly differ between obstructed and non obstructed groups. The reported prevalence is less than suggested in previous studies. This may be a response to the direct method of questioning used compared to postal questionnaires utilised by previous studies. Furthermore, patients referred for urodynamics represent a subset of the general population targeted by postal questionnaires.
Conclusions
There is a significant prevalence of reported erectile dysfunction (27%) in male patients referred for urodynamics. However, there is no evidence to suggest that the presence of urodynamic obstruction increases the prevalence of erectile dysfunction. In radical retropubic prostatectomy (RRP) for prostate cancer it is believed that a positive surgical resection margin or a histological stage T3a tumour leads to a worse outcome. We have prospectively analysed PSA recurrence and mortality in our series of patients.
Methods:
We have followed-up 473 consecutive RRPs performed by two consultant urological surgeons over a 12 year period. All patients were white caucasians. Median follow-up was 4 years (range: 1-12).
Results:
There were 294 specimens without capsular penetration (T2), but tumour was seen at the margin (T2+) in 23(7.8%). 4 (17%) of this group have a recordable or rising PSA level compared to 40 (15%) in the margin negative group. Of 163 resected specimens with capsular penetration (T3a), 102 (63%) had tumour at the margin (T3a+). 52 (51%) of this group have a recordable or rising PSA level compared to 11 (18%) in the completely excised group (p <0.0001, Chi 2 ). Disease specific survival after all RRPs remains >99%.
Conclusions:
There are equivalent relapse rates in pT2, pT2+ and pT3a (with negative margins) tumours. However a 50% PSA relapse rate exists in the pT3a+ group which is significantly higher (p <0.001 Chi 2 ) and may benefit from early adjuvant therapy. However, the use of extended TRUSB protocols in men with high PSA values remains controversial. Our study aimed to evaluate the cancer detection rates on an individual core basis, to establish an optimal biopsy protocol for various PSA levels.
Patients and methods
195 consecutive patients with PSA ranging from 4ng/ml to 584ng/ml who underwent TRUSB (ten cores) over a six month period were assessed. The four peripheral biopsies were directed more laterally at the base and apices. The remainder were standard para-sagittal sextant biopsies. The biopsies were performed in a standardised fashion with antibiotic prophylaxis. The cores were placed in separate pots and histopathological findings analysed. Patients were stratified into three PSA groups (PSA <20ng/ml, PSA 20 -50ng/ml and PSA >50ng/ml) Results Mean age of the 195 patients was 69.8years (range: 44-96 years). Cancer was detected in 100 patients (51%). Cancer detection rates were 40% (<20ng/ml), 83% (20-50ng/ml) and 100% (>50ng/ml) respectively. All 24 cancers in men with PSA 20-50ng/ml would have been detected with a six core biopsy protocol (Figure 1 ) and the 16 men (PSA >50ng/ml) with cancer would have had their diagnosis confirmed with a four core biopsy protocol (Figure 2 ). Conclusion TRUSB in men with PSA >20ng/ml did not require 10 cores to diagnose prostate cancer. Prostate cancer diagnosis required only six cores in men with PSA 20 -50 ng/ml and four cores in men with PSA >50 ng/ml. Our study showed that the extended TRUSB protocols are unnecessary in men with high PSA values (PSA >20ng/ml) and suggest limited biopsy protocols for men with high PSA values. Figures   Fig.1 (3):455-60). In order to elucidate resistance mechanisms to gefitinib, we previously generated a DU145 prostate cancer cell line with acquired resistance to the inhibitor (DU145/TKI-R) and demonstrated that the δ isoform of the protein kinase C (PKC) family was elevated in the gefitinib resistant variant (Jones et al. Endo-Rel Cancer 2004; 11:793-814) . Multiple PKC isoforms exist, which play important roles in signal transduction pathways mediating numerous cellular processes including cell proliferation, differentiation. In this study, we examined the involvement of several PKC isoforms in the acquisition of resistance to gefitinib in the DU145 model of prostate cancer.
Methods:
Wild type (WT) DU145 and DU145/TKI-R variant prostate cancer cell lines were used in this study. Alterations in the expression/activation and/or localization of various PKC isoforms was assessed using Western blotting and immunocytochemical techniques respectively. Cell proliferation in response to several PKC inhibitors was evaluated by anchorage dependent growth.
Results:
Compared with the parental DU145 cells, the DU145/TKI-R cells showed significant increases in the levels of phosphorylated PKC-δ and PKC-µ isoforms whereas amounts of phosphorylated PKC-α, -βII, -ζ, -λ  and -θ were unaltered. Subsequent immunocytochemical assessment of PKC-δ and -µ further indicated a differential localization of these two isoforms in the gefitinib resistant phenotype. In WT DU145 cells, basal PKC-δ is detected in both nuclear and cytoplasmic compartments but in the DU145/TKI-R cells, it shows a dramatic increased nuclear localisation. In addition, basal PKC-µ expression appears to display a pattern consistent with Golgi localisation in WT DU145 cells, whereas in the DU145/TKI-R variant cells, the protein shows a distinct association with the cell membrane. The DU145/TKI-R cells also showed a significant increased sensitivity to challenge with the PKC inhibitors a) Ro-31-8220 (0.05-0.75µM), a non-selective inhibitor and b) rottlerin (0.5-1µM), an inhibitor which shows some selectivity for PKC-δ. Both parental and gefitinib resistant cells showed similar growth inhibitory responses after challenge with Go6976, an inhibitor with preferential selectivity for PKC-µ
Conclusion:
In prostate cancer cells, acquired resistance to gefitinib is associated with increased signalling through PKCs. Although other isoforms including PKC-µ contribute to the maintenance of growth, the results suggest that PKC-δ may play a more dominant role in the gefitinib resistant cells. Moreover, the striking differential localization of PKC-δ and PKC-µ in the gefitinib resistant phenotype implies that these kinases are involved in different biological roles in this variant cell line Introduction TURP is a common operation performed by all grades of urologist and could be an important area of clinical governance. This study aimed to ascertain whether measuring post-operative blood loss divided by prostate weight resected could be used as a measure of trainee competency.
Materials and Methods
The study was divided into two parts: a retrospective component (from 1/10/1997 to 31/8/2000) and a prospective arm (from 1/10/2000 to 31/9/2002). 4 consultants, 1 staff grade and 13 trainees' results were analysed. The outcome measures were haemoglobin reduction over 24 hours, weight resected, transfusion requirements and histology. Clinicians were aware of the results of the first part of the study during the prospective component, when supervision was increased for all trainees. Results 1517 operations were performed over the five-year period with complete data in 1131 cases. 733 procedures were in period 1 and 398 in period 2. In period 1, 6.7% of the patients required transfusion (mean 3 units) with a mean haemoglobin drop of 0.856g/dL and mean resection weight of 16.9g. 2.5% of patients from period 2 were transfused (mean 2.5 units), with a mean haemoglobin loss and prostate weight of 0.845g/dL and 18.5g respectively. The ratio of haemoglobin loss per gram of tissue resected decreased in period 2 versus period 1 and also with increased experience. Trainee ratios improved from a maximum of 141% above the mean consultant ratio to 41% above. All trainees' results improved in period 2.
Conclusion
The number of TURP's decreased annually in line with national trends. Despite this, all grades of surgeon are able to produce satisfactory results, even early in their training, if they are suitably supervised.
Introduction
Cross-sectional imaging is routinely employed to confirm staging of Prostate cancer, particularly where radical surgery is an option. We sought to assess the role and implications of cross sectional imaging in patients with T1c disease. Methods Data was collected from our oncology database for a period of 3 years, ending October 2004, where all new prostate cancers are recorded. Gleason grade, clinical stage, cross-sectional imaging result and subsequent treatment were also recorded. Results A total of 644 patients were diagnosed with prostate cancer, of which 147 patients had T1c disease. 91 of these patients were considered as candidates for radical treatment and underwent cross-sectional imaging (MR scan). 87 patients had negative scans, two were equivocal, subsequently proving to be negative, one was falsely positive and in one case only was the disease was upstaged to T3. Imaging results affected treatment choice in only one patient wherein radical surgery was not offered based on the scan findings. The mean PSA was 8.1 (0.6 to 86ng/ml), the mean Gleason score 3+3 (1+2 to 5+5). The mean age of the group that underwent cross-sectional imaging was 62.3 years, against 72.7 years for the other group, reflecting the age bias in being considered for a radical prostatectomy. Patients with a PSA greater than10ng/ml underwent a bone scan. Conclusions Routine cross sectional imaging is not necessary in patients with T1c prostate cancer and should be reserved for patients with equivocal clinical findings.
Chronic Pelvic Pain Syndrome is poorly understood and remains a diagnostic and therapeutic challenge. Neural hypersensitivity may be involved in the aetiology of this pain and some studies have suggested the role of modulation based therapy. The aim of this study was to assess the benefit of Stoller's Afferent Nerve Stimulator (SANS) for these patients. Materials and methods 8 patients with abacterial chronic prostatitis (National Institutes of Health Type III) underwent percutaneous electrical stimulation of the posterior tibial nerve using the SANS stimulator. They attended a thirty minute session each week for twelve consecutive weeks. Patients were evaluated at 0, 4, 8 and 12 weeks using the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). They also completed a validated visual analogue score and pain diary. Results 7 patients completed the study, with improvements in 5. The average NIH-CPSI scores (maximum 43) were 25.7, 22.1, 20.1 and 16.6 at 0, 4, 8 and 12 weeks. Visual analogue scores fell from 1.8/5 at baseline to 1.1/5 at 12 weeks. The average pain diary score improved by 12% (2/5 before starting and 1.4/5 at completion) Conclusion Preliminary data suggests SANS is a promising option for this group of patients although further larger studies are required to assess the reproducibility of these responses.
PSA stability prior to radical prostatectomy. Is it a problem or a concern? Jonathan P Dyer, Andrew Adamson Royal Hampshire County Hospital, Winchester, Hampshire
The journey from suspected carcinoma of the prostate to treatment by radical prostatectomy (RP) can be a long one, drawn out by investigations and appraisal of the ever increasing number of treatment options. PSA, clinical stage and Gleason grade help predict risk of non-localised disease which in turn underpins the decision making process. This study aimed to investigate how one of these parameters, PSA, varied over the workup period prior to RP and whether such change would alter choice of investigations, suitability of treatments and surgical approach. 
Patients and Methods
Materials and Methods
RT-PCR was used to analyse the expression of semaphorin 4D and plexin B1 in normal and prostate cancer cell lines. Real time RT-PCR performed on a Taqman 7700 was used to quantify plexin B1 mRNA expression. Immunofluorescence of transiently transfected cells was used to investigate localisation of plexin B1. To investigate the role of plexin B1 in cell migration and metastasis, a collapse assay was used. Results Semaphorin 4D and plexin B1 mRNA was expressed in all normal and prostate cancer cell lines. Higher levels of plexin B1 was found in the prostate cancer cell line, LNCaP which was derived from a lymph node metastasis. Plexin B1 protein was shown to be expressed on the cell surface. Cells cotransfected with plexin B1 and Rnd collapse.
Conclusion
The semaphorin signalling pathway may be involved in prostate cancer progression. Using the cell collapse functional assay, further protein interactions of plexin B1 will be determined. Of the 122 patients which overstayed, 75(61.4%) were discharged by day 7. Postoperative complications were the most common cause of increased hospitalization in 63.1% cases. UTI (30 cases, 5.5%) was the commonest post operative complication. Active bleeding requiring a blood transfusion was seen in 17(2.9%) cases. Major complications developed in 24(4.1%) patients, of whom 22(91%) required a hospital stay greater than 7 days. There was no intraoperative or postoperative death. Of the different variables preoperative comorbidity (Spearman's 'r'=0.4562, P=0.0003), indication of operation (with retention, P<0.0001), timing of operation (initial admission, P<0.0001) and postoperative complications (Spearman's 'r' = 0.6782, P<0.0001) strongly correlated with prolonged hospital stay. A weak or no correlation was seen in the remaining variables.
Preoperative
Conclusion:
Postoperative complications were the most common cause of prolonged hospital stay. Preoperative co-morbidity, postoperative complications, indication and timing of operation positively correlated with prolonged hospital stay. Clinical care pathways have been used effectively in health care cost management by reducing the hospital stay. However, individuality of patients based on these variables may help in further refining of these pathways.
Incidental acute prostatic inflammation is associated with a lower percent free PSA than other benign conditions of the prostate E. Rowe, M. Laniado, M. Walker, A. Patel St Mary's Hospital London
Introduction:
The aim of this study was too assess the incidence of asymptomatic prostatic inflammation in men screened for prostate cancer, and to compare percent free PSA (%fPSA) values to those in men with prostate cancer and benign prostatic tissue only at biopsy. The impact of prostatic inflammation on the performance of %fPSA as a screening tool for prostate cancer was evaluated.
Materials and Methods:
Men aged 50 to 65 years were invited for prostate cancer screening. Biopsies were performed in men with a total PSA ≥4ng/ml, together with those with a PSA between 1.1 and 3.99ng/ml and a %fPSA ≤20%. Histological evidence of prostate cancer, acute inflammation, chronic inflammation, and benign prostatic tissue were noted in biopsy cores, with the associated %fPSA values.
Results:
The cancer detection rate was 4.3%(33/773). Evidence of inflammation was found in approximately 50%(87/175) of those biopsied. Men with acute inflammation, 15.4%(27/175), had significantly lower serum %fPSA values (mean 13.4%) compared to those with chronic inflammation (mean 16.6%, p = 0.0021) and benign prostatic tissue (mean 15.7%, p = 0.0337), but were similar to men with prostate cancer (mean 15.3%, p = 0.3148).
Conclusion:
In this prospectively screened cohort of men, there was a high incidence of asymptomatic inflammation on prostatic histology. %fPSA was significantly lower in men with acute inflammation. This finding may explain the variability of %fPSA in improving specificity when used as a screening tool for prostate cancer, and may also reduce its effectiveness in differentiating tumours with more aggressive potential.
Percent free PSA is inversely proportional to pre-operative predictors of significant disease: A prospective screening study E. Rowe, M. Laniado, M. Walker, A. Patel St Mary's Hospital, London
Introduction:
To assess the relationship between percent free PSA (%fPSA) and recognised pre-operative indicators of significant prostate cancer including: Gleason sum, PSA density (PSAD), percentage of the biopsy cores affected, clinical stage, and total PSA.
Materials and Methods:
Men between the ages of 50 and 65 years were invited for prostate cancer screening. None had previously undergone screening for prostate cancer. Biopsies were offered to all those with a total PSA ≥4ng/ml, and those with a total PSA between 1.1 to 3.99ng/ml and percent free PSA ≤20%. In those found to have prostate cancer, the relationship between %fPSA and: Gleason sum, PSAD, percentage of cores affected, clinical stage, and total PSA was evaluated.
Results:
Seven hundred and seventy three men were screened. The cancer detection rate was 4.3%(33/773). This included 33%(20/60) of men with a PSA ≥4ng/ml, and 11.3%(13/115) of those with a PSA between 1.1 and 3.99ng/ml and percent free PSA ≤20%. There was a significant inverse relationship between %fPSA and: Gleason sum ≥7 (P = 0.02), PSA density (p = 0.0001), percentage of cores affected (p = 0.0012), clinical stage (p = 0.0021), but not total PSA (p = 0.0855).
Conclusion:
Percent free PSA may allow the differentiation of the more significant forms of prostate cancer. In this prospectively screened cohort of young men the relationship extended to those with a 'normal' total PSA. 
Introduction:
Radical retropubic prostatectomy is an established treatment for localised prostate cancer. Both open and laparoscopic approaches are reported to be safe and oncologically sound in experienced hands.
Materials and methods:
We report a comparison of the learning curves for the first 75 open and 75 extraperitoneal laparoscopic procedures performed by a single surgeon after becoming a Consultant.
Result:
The baseline characteristics of open and laparoscopic groups were similar; median ages of 60.7years and 64.2years, T1c disease in 55.6% and 55.9%, a median pre-operative PSA of 6.8ng/ml and 6.7ng/ml respectively, and a median Gleason score of 3+3 for both groups. The table lists outcome measures in groups of 25, divided by approach.
Conclusion:
The results and complications are discussed. 
Methods
We performed a retrospective review of 115 patients who attended a one-stop prostate clinic over a one-year period and recorded biopsy rates, diagnosis and whether they did or did not receive prior counselling. Results 64 patients (56%) had received counselling and 51 had not (44%). 40 new cases of Ca Prostate and four new cases of PIN were detected (detection rate = 61%). We found that patients who received counselling were more likely to have a biopsy than those who had not (35/52; p < 0.05, chi-square).
Conclusions
Despite recommendations, 44% of the new patients attended the one-stop clinic without receiving any counselling. Importantly, the patients who were counselled were more likely to proceed to a biopsy than the ones who were not counselled. This highlights the need to raise the referring practitioners' awareness regarding PSA counselling. We have now designed an information leaflet that is sent to patients with details about PSA counselling and are re-auditing the effect this is having on uptake of TRUS biopsy rates.
Introduction
There is an ever-increasing focus on chemo-preventative measures to curb the rising incidence of prostate cancer. The natural dietary product lycopene derived from tomatoes has been shown to accumulate in the prostate gland and reduces the risk of developing prostate cancer in persons with a high intake of tomato products (Giovannucci et al. J Natl Cancer Inst 1995; 87: 1767) . Studying the mode of action, accumulation, distribution and handling of intracellular lycopene remains elusive to conventional methods of cellular imaging. Traditionally analysis of lycopene in cells and tissues has been by means of high performance liquid chromatography, limited to studies on tissues extracts. Raman spectroscopy is a novel imaging modality that overcomes this. Acquisition of Raman signals generated by the inelastic scattering of incident monochromatic light due to the vibrational distortion of molecular bonds confers a unique signature to the compound of interest, thereby allowing its detection and potential image generation.
Materials and Methods
Monolayers of malignant prostatic epithelial cells (PC3) were grown in cell culture medium, on Calcium Fluoride slides. Once the cells had reached 80% confluence they were exposed to 4.65 micromoles/ litre lycopene. Following an incubation period of 18 hours they were imaged using Raman microspectroscopy (Renishaw Ramanoscope) to see whether lycopene was detectable within the cells. Raman spectra were obtained from intracellular regions following excitation with 830 nm wavelength incident laser light. Results Signal peaks corresponding to vibrational energy of molecular bonds within lycopene were detectable from within the cells, after background subtraction.
Conclusion
It is possible to detect intracellular lycopene in malignant prostatic cells. Raman spectroscopy offers a novel way of studying this important chemopreventative agent in its native form. Furthermore, it allows imaging of lycopene in single live cells and in real-time. Determination of the exact intracellular distribution, pharmacokinetics, full imaging and even quantitation is feasible.
Introduction
As the population ages, urological workloads are increasing. The management of Lower Urinary Tract Symptoms (LUTS) is a significant part of the urological workload. Whilst some of this work can be performed by a specialist nurse there is a significant investment in time, effort and money for both training and validation of his or her abilities. We set out to develop a computer expert system, the operation of which could be learnt in 15-20 minutes and when used by a nurse provide safe and appropriate advice which could be directly communicated to a patient's GP.
Materials and Methods
The software is internet based and database driven. It manages the condition with knowledge of previous treatments and results. The algorithm is based on guidelines issued by BAUS and EAU. The software interprets indices suggested by the guidelines (e.g. IPPS, bother score, flow rate etc.) as well as the presence of haematuria, age-related PSA and the effect of medications on PSA amongst other factors. Management advice is in the form of a computer generated letter written in plain English to the GP. This summarises the information gained, advises on further relevant examination/tests, clinical management and follow up. Consecutive patients were entered from our LUTS database. Our working hypothesis is that the MEK5/ERK5 pathway plays a key role in CaP progression and may represent a target for therapy. Therefore, immunostaining for ERK5 and MEK5 has been performed on a range of resected prostate cancer samples to further delineate its function and clinical significance.
Methods:
A cohort of resected human CaP tumours (n=83) with median Gleason sum score 8 (range 4-9) and median age 73 years (range 65-89) were immunostained with anti-ERK5 and anti-MEK5 antibodies. 20 cases of benign prostatic hyperplasia (BPH) were included as controls. Two independent observers (including a consultant uro-pathologist) scored the intensity of staining as negative (0), weak (1), moderate (2) or strong (3), and the results correlated with Gleason grade, presence of bony metastases and survival.
Results:
The BPH specimens all stained negative/weak for ERK5. Increased ERK5 staining is seen with increasing Gleason grade (p<0.0001) and correlates closely with MEK5 staining (p=0.0053). Higher ERK5 cytoplasmic staining intensity was seen in patients with bony metastases compared to those without (p =0.0044). A Kaplain-Meier Survival plot revealed that higher ERK5 cytoplasmic expression is associated with less favourable survival than the group with less ERK5 staining (p=0.0361). Interestingly, a subgroup of cancers existed with strong nuclear ERK5 expression (n=15). A Kaplain-Meier Survival plot revealed that ERK5 nuclear expression is also associated with poorer survival, irrespective of cytoplasmic expression (p=0.0053) or Gleason grade (p=0.0009). Multivariate analysis revealed that ERK5 nuclear expression is an independent prognostic marker in CaP.
Conclusion:
These data demonstrate further evidence that the MEK5/ERK5 pathway is important in prostate carcinogenesis, and may prove to be an attractive target for future therapies. ERK5 nuclear expression may have an important role in disease stratification.
Introduction
T1a prostate cancer is an uncommon subgroup of prostate cancer and currently there is no uniformly accepted management protocol for it. The 1999-2002 BAUS cancer database shows an apparent preference for these patients to be managed with surveillance. Outcome data of this management approach are poorly described. We report the management and outcome of series of 50 UK patients with T1a prostate cancer. 
Methods
Introduction:
Operative intervention for bladder outflow obstruction secondary to large (>80cc) prostates can be challenging. We report operative, 3 and 12-month outcomes with Photoselective Vaporisation of the Prostate (PVP), a novel treatment modality.
Patients and methods:
30 patients with prostate size 80 cc or greater as measured by on-table transrectal ultrasound underwent PVP using a high power 80W KTP laser. 19 patients were symptomatic voiders while 11 were chronically catheterised.
Results:
Mean prostate volume and operative time for symptomatic voiders was 104cc and 83mins respectively. However catheterised patients had a mean prostatic volume of 107cc and a mean operative time of 80mins. There were 50 T1a patients diagnosed following TURP Complete data were available for 37 patients with a mean age of 70 years (range 56-88), mean PSA of 5.47(range 29-0.7) and a mean Gleason Score of 4.4 (range 2-7). All but 6 patients ha significant comorbidities.
Two patients were offere immediate treatment and 35 patients underwent active monitoring. The mean follow up in our group was 5 years (range 1-11yrs). 18 patients died during follow-up. While the exact cause of death is unknown in most of these patients, none had a very high or significantly rising PSA prior t death,suggesting that they died of other causes than prostate cancer. 22 of the 32 alive patients (61%) showed an increase in PSA during their follow up, but only 5 patients (13.5%) showed significant rise (PSA doubling time < 2 years) and these were offered treatment (hormones=4, radiotherapy=1) None of these patients developed hormone resistant disease during mean follow-up of 5.4 years. Two patients on activ monitoring required further TURP. Conclusion Active monitoring is an appropriate and safe initial management approach for most T1a prostate cancer patients. Only 1 symptomatic voider and 4 chronically catheterised patients required a catheter for greater than 1 night.
Conclusion:
Photoselective vaporisation of the prostate provides a safe and effective alternative to TURP. The minimal bleeding enables large prostates to be treated with a short hospital stay and catheterisation time.
Do we need Chaperones for Digital Rectal Examination?
Ong, E; *Garnett, S; *MacFarlane, J; Donat, R Department of Urology, Western General Hospital, Edinburgh EH2 4XU *Department of Urology, Queen Margaret Hospital, Dunfermline KY12 0SU
Introduction:
General Medical Council (GMC) guidelines and the recent Ayling Report on intimate examinations recommend that a chaperone should be offered to all patients regardless of the examining doctors' gender. We wanted to establish whether these guidelines reflect male Urology patient's preferences and Urologists' current practice in intimate examination.
Materials and Methods:
A questionnaire with 8 items was given to all male patients attending Urology clinics at two hospitals over a four weeks period. A separate questionnaire with 8 items was sent to all urologists in Scotland to establish the current practice. 
Introduction:
Financial demands in the optimal delivery of urooncological services prompt ways of cutting costs. We developed a costings prediction model (CPM) to evaluate the cost of laparoscopic radical prostatectomy (LRP) and open radical retropubic prostatectomy (ORP). Herein we tested the model to find how accurately we could predict the cost of a typical case of LRP vs. ORP.
Materials and methods:
The costings model consists of a computer-aided programme into which cost variables were added. Consultants from two tertiary referral centres were asked to provide the costs of ten ORP and ten LRP cases. The cost of each case was tabulated and the CPM applied to generate a predicted cost and actual cost. The accuracy of the model was evaluated.
Result:
The cost of LRP is greater than RRP by a factor of 1.7. Our costings prediction model was able to accurately determine the cost of an LRP vs. RRP in 8/20 (40%) cases within £50 and 100 % of cases within £100.
Conclusion:
Cost estimation using a costings prediction model (CPM) is an accurate tool in performing the cost analysis of laparoscopic vs. open radical retropubic prostatectomy. When establishing a financial feasibility study in the NHS or in the private sector, a costings model can be used to generate the estimated cost of a maximally vs a minimally invasive procedure. In the current climate of health economics such tools are required to validate the health burden of one treatment option versus another. improvements in technique and understanding of the mechanisms of cryo-induced injury in the prostate have led to renewed interest in this treatment option for patients with prostate cancer. One of the main unresolved issues is the economic impact and health burden of this treatment modality in relation to other management options. We conducted a preliminary analysis and comparison of the hospital costs of radical prostatectomy (RP) and CP in the U.K. setting.
Materials and methods:
Ten RP and five CP patients were selected and analysed using a platform computer generated costings template. Costs were obtained from the hospital accounting office, theatre managers and from company representatives. Consultant fees and room costs were omitted.
Results:
Average hospital costs were £ 1670 for men undergoing CP and £ 394 for men undergoing RP. The average length of stay was 1 day for CP and 7.5 days for RP. The CP cost is lowered by the current multi-case packages offered by companies.
Conclusion:
As costs become an ever more critical factor in healthcare, the costs of treatment options for clinically localized prostate cancer will become as important as clinical outcomes in deciding appropriate treatment. The shorter stay in hospital for CP is likely to balance the cost of longer stay in RP. From a strictly financial perspective, CP is a viable treatment option for clinically localized prostate cancer. Large-scale studies are indicated to further appreciate the cost implications of cryosurgical ablation of the prostate.
Introduction
Current dosimetric evaluations of permanent prostate brachytherapy implants typically rely on either CT or MR images. Both of these modalities are suboptimal due to difficulties in outlining structures efficiently and identifying seeds with accuracy. We explored the use of "XMR" (comprised of a 1.5T Philips Intera scanner and a Philips BV Pulsera mobile X-ray set) which combines MR imaging with fluoroscopic C-arm X-rays to provide images for improved dosimetric evaluation.
Materials and Methods
A previously implanted 67 year old patient was imaged in the XMR suite. MRI and X-ray image registration was achieved through a combination of calibration and real-time tracking. A fusion algorithm was created to register the X-ray imaged seeds onto the MRI volume. Varian7.1 software was used to carry out dosimetric evaluation on the resulting MRI images with superimposed seed positions. 
Introduction:
AS or "Watchful waiting" is one of the treatment options in prostate cancer. In considering AS, the chances of progression must be weighed up against the morbidity associated with radical treatments.
Patients and methods:
Prospectively 34 patients with prostate cancer who had chosen AS as their initial treatment were followed-up. The mean age was 69 years (50 -91) with a median presenting PSA of 7.6 ng/ml (1.5 -179).
Results:
At median follow up of 29 months (1 -120), 20 men (59%) had PSA values that remained static or had reduced. 4 men (12%) had a rising PSA but remained on surveillance. 5 men (15%) had additional treatment: 1 had hormonal suppression; 3 have had radiotherapy (all with current PSA <1 ng/ml) and 1 had a radical prostatectomy (PSA undetectable). There was one death (presenting PSA 179, aged 91). 4 men (12%) were lost to follow up.
Conclusion:
AS remains a useful treatment option. Most men in this series have a stable PSA and over two thirds have avoided radical treatment with no obvious adverse effects in outcome. This regime helps to reduce the costs of treatment both in terms of the side effects and the financial cost.
The role of radical prostatectomy in patients with high preoperative prostate-specific antigen (20 ng/ml or above).
B.E. Drake, D.A. Gillatt Bristol Urological Institute, Southmead Hospital, Bristol, England
Objective:
To present our experience of radical prostatectomy (RP) in patients with a prostate-specific antigen (PSA) of 20ng/ml or greater. Patients and methods: 500 patients had RP under the care of a single consultant. 73 of these presented with a PSA of 20ng/ml or above. 3 patients were excluded from analysis as RP was not performed due to positive pelvic nodes being found at operation.
Results:
Of the 70 patients 26 were referred from other centres. The mean age was 64 with an average PSA of 27.9ng/ml. 11 out of the 70 patients analysed had adjuvant hormonal therapy. The mean follow up was 5 years 6 months. 11 patients (15%) had seminal vesicle involvement, the mean PSA in this group was 36.5ng/ml compared to 26.6ng/ml in those without involvement. Post operatively 88% of patients were fully continent with 40% being potent. 54% and 30% of patients showed no biochemical recurrence at 3 and 5 years respectively. 3 patients died from their disease during follow up.
Conclusion:
Whilst the disease free survival rate is lower in those with a PSA of 20 or above, this study suggests that RP has a role in treating patients with a high PSA.
Seminal Vesicle involvement after radical prostatectomy -a single centre experience B.E. Drake, D.A. Gillatt Bristol Urological Institute, Southmead Hospital, Bristol, England
Objective:
Seminal vesicle involvement (SVI) at radical prostatectomy (RP) is considered to be a poor prognostic indicator. We present data on 56 cases. Patients and methods: 500 patients underwent RP over a 14 year period under the care of a single consultant. 56 patients were identified from this database with SVI. 24 of these patients had been referred from other centres. The mean follow up was 39 months (range 3 -112).
Results:
The mean prostate-specific antigen (PSA) at presentation was 16.2ng/ml (range 1.5 -67ng/ml) with a median Gleason sum of 6 at biopsy and 7 at operation. 3 patients had node positive disease. Post operatively 95% regained continence whilst 35% were potent. The low potency figure reflects decreased neurovascular bundle preservation. At 3 years 40% showed no biochemical recurrence. 5 patients died during follow up, 3 of these from unrelated causes. There is no statistical difference between Gleason grade at operation and mean time to recurrence (p>0.1).
Conclusion:
SVI does appear to indicate poorer outcome post RP. Reliable methods of determining invasion are required pre-operatively. 
Results
Using semi quantitative PCR we observed strong expression of hSef in the androgen dependent LNCaP and androgen independent PC3 cell lines. Androgen independent DU145 cells expressed extremely low levels of hSef. In an extended series of prostate cancer cell lines we observed that more metastatic derivative cell lines (LN3 and PC3M) appeared to express lower levels of hSef compared to parental cell lines (LNCaP and PC3 respectively). In both PC3 and PC3M cell lines, FGF treatment had no effect in inducing hSef expression. Treatment of DU145 cells with 5-AZA C however did not appreciably alter the very low levels of hSef expression. In clinical tissue positive hSef expression was seen in 80% of benign prostate biopsies, 57% of cancer biopsies and 40% hormone refractory disease. Loss of hSef expression was significantly associated with increasing Gleason sum score (p=0.01) and the incidence of bone metastasis at presentation (p=0.01). In pure epithelial cell populations from fresh frozen prostate biopsies the highest levels of hSef was observed in benign micro dissected glands. In comparison, higher Gleason grades of malignant glands expressed progressively lower levels of hSef transcript consistent with our data from in situ hybridisation studies.
Conclusion
These data suggest that the expression of hSef, a FGF signalling inhibitor is lost in prostate cancer progression. 
Introduction
Recent studies have demonstrated a direct correlation between prostate volume and serum PSA in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic enlargement (BPE) (1). There is also evidence that PSA is correlated with the obstruction grade defined by invasive pressure flow studies (PFS) (2). Taken together it would appear that increasing prostate volume results in increased PSA, increased IPSS and reduced Q max (3). The aim of our study was to investigate the predictive value of PSA in relation to outcome from TURP.
Subjects and Methods
Patients undergoing elective TURP at our institution for treatment of LUTS presumed secondary to BPE were invited to enter a prospective study investigating the predictive value of non-invasive PFS. As part of their assessment the preoperative PSA, if measured, was recorded. Following informed consent, men who agreed to participate in the study underwent an identical assessment before and 4 months after TURP, including IPSS and QOL score, uroflowmetry and non-invasive PFS with the penile cuff device. The pre-defined criterion for a successful outcome was a 50% reduction in total IPSS. Differences in serum PSA values between patients with successful outcome and those with poor outcome were assessed using Student's 't' test. A receiver-operator characteristics (ROC) curve was constructed to define the pre-operative PSA level, which optimized prediction of successful outcome following TURP.
Results
To date 64 patients with mean (range) age 69 years (56-84) have been reviewed from a target sample size of 200. Postoperative IPSS score showed that 48 men (75%) had a good outcome. The mean (s.d) pre-operative PSA in this group was 6.7 (9.7) ng ml -1 compared to 2.3 (2.2) ng ml -1 in those with poor outcome (P<0.01) .ROC analysis showed the optimum value of pre-operative PSA for prediction of satisfactory outcome of TURP was 2.5 ng ml -1 with sensitivity 65% and specificity 75% (ppv = 89%). Conclusion These initial results suggest that PSA may be useful as a predictor of outcome following TURP. It therefore has potential use in the evaluation of men suffering from LUTS to guide individual management. Although our initial results are encouraging and we realise their preliminary nature and appreciate the need to complete data collection on all men entered into the prospective study. 
Can
Introduction
Prostate specific antigen (PSA) levels can vary widely in individual patients over time. This has led to some doubt over the significance of a single raised PSA. We studied the patterns of PSA variability prior to prostate biopsy and correlated this with biopsy outcome.
Materials and Methods
The Northern Ireland Cancer Registry maintains an electronic register of all PSA tests performed in Northern Ireland. Using unique identifiers, repeat PSA tests for each individual are identified. This information is linked to the cancer registry which uses hospital discharge systems and histopathology data to identify men who underwent a prostate biopsy, with its outcome. The serial PSA levels before the biopsy were categorised into 4 groups based on the pattern of results. Group 1 showed a steadily increasing PSA. Group 2 had an increasing trend, however had at least one PSA level which was lower than the preceding PSA but not below the baseline level. In group 3, the PSA fell at some stage to below the baseline level but not to the normal range. In group 4, the PSA decreased to normal levels at some time point. The Student's t-test and Pearson chi-square were used to assess statistical significance.
Results
Between 1994 and 1997, 17323 men aged less than 60 years old had their first PSA test. 1414 had a moderately elevated PSA (above age-specific reference range and below 10ng/ml). Of these, 301 men had a prostate biopsy with 71 (23.6%) having cancer and 230 (76.4%) having a benign biopsy. A total of 1255 PSA tests were performed in these 301 men (934 in benign cases, 321 in cancer cases). The mean number of tests prior to diagnosis of cancer was 4.5 compared to 4.1 in benign cases (NS). The mean baseline PSA was 6.18 ng/ml and 5.73 ng/ml in the cancer and benign groups respectively (NS) with a mean change in PSA of 6.95 ng/ml vs. 1.28 ng/ml (p<0.001). 46(15.3%) patients had only one PSA test (32 benign, 14 cancer) and so trends were not available. Of the 57 cancer patients, there were 13 (22.8%) in group 1, with 20 (35.1%), 10 (13.9%) and 14 (24.6%) in groups 2, 3 and 4 respectively. This compared to 43 (21.7%), 37 (18.7%), 62 (27%) and 56 (28.3%) in the benign group (p < 0.05). The majority of cancer patients had a group 2 pattern with the majority of benign patients having a group 3 pattern. 22.8% of cancer patients had a steadily increasing PSA (group 1 pattern) while 24.6% had a PSA which returned to normal at some point (group 4 pattern). The group 1 pattern was only associated with a subsequent diagnosis of cancer in 23.2% (13/56) of cases, with a group 4 pattern having cancer in 20% (14/70) of cases. None of the individual patterns showed any significant differences between benign and malignant biopsy outcomes. Conclusion PSA varies widely in individual patients over time. The PSA variability pattern does not appear to differentiate a benign from a malignant prostate reliably, with the majority of men showing occasional decreases in PSA levels. A decreasing PSA level should not delay performing a prostate biopsy. Repeat PSA testing after an initially raised level, even when the PSA returns to normal, can rarely identify those who do not require prostate biopsy. Biopsy may therefore be most appropriate after a single abnormal PSA.
Sumoylation of Tip60
Stuart Ferguson*, Luke Gaughan and Craig Robson. Urology Group, Northern Institute for Cancer Research, University of Newcastle Upon Tyne, UK.
Introduction:
Prostate cancer is the most prevalent cancer in western men and accounts for approximately 35,000 deaths a year in Europe alone. Standard treatment of prostate malignancy, including surgical or chemical castration, is largely ineffective and potentiates the formation of a more aggressive androgenindependent tumour to which there is currently no treatment.
The mechanisms involved in the transition from androgendependent to androgen-independent cancer remain ill defined. The androgen receptor (AR) is a ligand-dependent transcription factor that plays an important role in prostate growth, homeostasis and in the formation of androgen-dependent andindependent cancer. AR-mediated transactivation is regulated in part by co-accessory proteins that enhance (co-activate) or attenuate (co-repress) AR activity. We have previously shown the histone acetlytransferase (HAT) protein Tip60 is a coactivator for the AR that enhances AR mediated transactivation by directly acetylating the receptor and is a component of the AR transcriptome upon the active androgen responsive PSA promoter. Given that sumoylation of the AR plays a fundamental role in regulating receptor activity, there may potentially be other targets for sumoylation in the AR transcriptome. Analysis of the Tip60 sequence suggests that the protein contains at least 2 potential I/L/VKxE sumoylation motifs. We investigated whether Tip60 is a direct target for sumoylation.
Materials and Methods:
Standard techniques using the COS-7 cell line and in vitro assays include, protein overexpression, co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (ChIP).
Results:
Tip60 is mono-and di-sumoylated, potentially at a C-terminal region containing the two consensus sequences. Furthermore, overexpression of Sumo in COS-7 cells enhances the stability of ectopically expressed Tip60. We demonstrate by coimmunoprecipitation that Tip60 interacts directly with Ubc9 and both co-associate upon the active AR-responsive PSA promoter using chromatin immunoprecipitation analysis.
Conclusion:
We have shown that Tip60 is sumoylated by Ubc9 in vivo and in vitro that enhances the stability of Tip60. The finding that Ubc9 associates with the AR and Tip60 upon the active PSA promoter suggests sumoylation of both proteins may occur at the promoter level and could regulate Tip60-mediated coactivation of the receptor. Further investigation will provide an insight into a novel mechanism of Tip60 regulation that may establish new therapeutic targets in prostate cancer. Traditional attempts at mapping loss of heterozygosity (LOH) or regions of local amplification in cancer using microsatellites and comparative genomic hybridization (CGH) are limited by the low resolution of the regions of genomic alteration that are identified. As a result the identification of the gene(s) frequently targeted in these mutagenic events are often difficult to identify. To overcome this problem we are using high resolution single nucleotide polymorphism (SNP) arrays to map the genomic alterations in prostate cancer cells. We are using the Affymetrix human mapping 10K 2.0 oligonucleotide array to genotype SNPs in genomic DNA extracted from malignant cells derived from prostate cancer biopsy specimens and patient matched peripheral blood lympocytes (PBL). This technology allows simultaneous genotype calling for 10,204 different SNPs distributed across the whole genome with a mean inter-marker distance of 258 kb.
Mapping genomic loss in
Comparison of the tumour and normal (lymphocyte) genotype allows identification of marker LOH and high signal intensities indicate amplified loci. Previous studies in our laboratories indicate frequent gene losses in prostate cancer at specific loci (8p21, 10q, and 16q) which act as landmarks in this more detailed genomic analysis. Furthermore, we have generated comprehensive gene expression profiles from the same tumour samples, using Affymetrix U133 plus 2.0 GeneChips. Comparing this dataset with expression profiles generated from benign samples allows us to define patterns of expression changes in this set of malignant samples. The combined SNP and transcriptional datasets allow linking of comprehensive maps of genomic alterations to the gene expression profiles to generate a unique depiction of the genetic changes underpinning this the development of this disease.
The role of androgen signalling in the regulation of human prostate epithelial stem cell differentiation Paul A Berry., Norman J Maitland., Anne T Collins YCR Cancer Research Unit, Department of Biology, University of York, York YO10 5DD.
Introduction:
Androgens play a pivotal role in the pathogenesis of prostate cancer and benign prostatic hyperplasia, yet little is known of the processes that influence the initiation or progression of prostate disease.
As stem cells are central to normal homeostasis and may be targeted in carcinogenesis, an understanding of the molecular basis of stem cell fate decisions will lead to insights into their disruption in prostate cancer and possible therapeutic targets. Stroma is the target and mediator of androgenic effects upon the epithelium, thus stem cell fate is likely to be regulated by the stroma.
Materials and Methods:
Stroma is a complex mixture of cell types, the majority of which are fibroblasts and smooth muscle cells. We have successfully cultured stroma from a range of patient's samples and determined the androgen receptor-positive cells within this complex mixture.
Results:
Androgen receptor (AR) is expressed in 16-55% of cells (n = 11) and the cells remain responsive to androgen over several population doublings. Cells expressing AR also express α smooth muscle actin, fibronectin and vimentin. Treatment with dihydrotestosterone (DHT) increased AR protein expression from 6-8h by Western blotting, but did not increase the number of cells expressing AR. Moreover, treatment with DHT decreased the level of expression of both smooth muscle actin and vimentin. Integrins are important in cell motility, migration and invasion. We have also identified stromal cells expressing AR and integrins including α1, α2 α2, α3, α6. Our results suggest there is a higher proportion of AR positive integrin α1, or α2 positive cells, than α3 and α6. Further, there is a lower proportion of integrin positive AR negative cells than the levels observed for actin, fibronectin or vimentin positive AR negative cells.
Conclusion:
Isolation of AR positive cells by α1 immunoprecipitation and binding to MACS beads will now allow us to sort AR positive cells from DHT treated cultures for Affymetrix GeneChip longer waiting time was associated with higher perioperative morbidity.
Material & Methods:
Out of 71 patients undergoing TURP over the three-month study period, 29 were found suitable for this study. Their age ranged from 61-95 yrs. 27 patients had a urethral catheter, 2 had a suprapubic catheter while awaiting TURP. 23/29 had longstanding LUTS prior to retention. 8/29 patients encountered catheter related complications prior to surgery. Only 6/29 patients had TURP within 6 weeks since catheterisation.
Results:
There were 7 pre-op episodes of catheter related complications and 3 unrelated events in a total of 8/29 patients. 6/29 patients had postoperative problems, only two of them possibly related to long-term period of pre-op. catheterisation. Incidence of catheter related morbidity was relatively higher during the preop than post-op period. 23/29 patients did not meet the national standards for waiting time to TURP.
Conclusion:
Complications related to prolonged period of indwelling catheter were noted mainly in the pre-op. period and only in those waiting more than six weeks. Although, local urethral discomfort was not quantified or qualitatively assessed in this study, 17/29 patients tolerated the catheter without significant catheter related problems. As the perioperative morbidity of catheterised patients awaiting TURP longer than six weeks is not overtly high, Urologists can afford to be more flexible in addressing the six weeks waiting time to TURP in the current environment.
